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ABSTRACT
Carboplatin is a chemotherapeutic drug, used for the treatment of different types of cancers, particularly
solid tumors. Carboplatin, like other platinum containing drugs, exerts its cytotoxic effect through DNA
binding via cross-linking. It forms interstrand and intrastrand cross-linking with DNA. Intrastrand cross-
linking is dominant and believed to be conferring antitumoral efficacy of the drug. This cross-linking
results in alteration of DNA winding and bending, which hampers DNA replication and transcription
and finally leads to cell death. In the present work, we studied the interaction of carboplatin with calf-
thymus DNA in buffer solution under physiological conditions. Different concentrations of carboplatin
were incubated with a constant DNA concentration to form carboplatin-DNA complexes. These com-
plexes were studied with Fourier Transform Infrared (FTIR) spectroscopy and circular dichroism (CD)
spectroscopy to understand the binding modes of carboplatin with DNA and its effect on DNA conforma-
tion. The results showed that carboplatin binds to DNA through direct interaction of platin-DNA bases
(guanine, thymine, adenine and cytosine), with a small perturbation of phosphate group of DNA back-
bone, while DNA remains in the B-conformation. DNA aggregation was also observed at higher drug
concentrations.
1. Introduction
Carboplatin is a cisplatin derivative, having bidentate cyclobu-
tane dicarboxylate (CBDCA) moiety as its leaving group in contrast
to the more readily leaving chloro groups of cisplatin (Fig. 1). Car-
boplatin is used to treat many types of cancer like ovarian carci-
noma, lung, head and neck cancers. It is increasingly used for
cancer treatment because of its advantage over parental drug cis-
platin in exerting lower side effects [1].
Although there are many theories to explain cytotoxicity med-
iated by platinum containing anticancer drugs, but covalent bind-
ing to DNA is believed to be responsible for their cytotoxicity [2-4].
They form interstrand and intrastrand cross-links with nitrogenous
bases of deoxyribonucleic acid. Intrastrand cross-linking is be-
lieved to be more important for platin mediated cytotoxicity [5].
Two adjacent guanines d(GpG) and, adjacent adenine and guanine
d(ApG) residues are involved in intrastrand cross-links. This cross-
linking results in unwinding and bending of the DNA duplex [6-8].
These changes in DNA structures hamper DNA replication and
transcription. Although there is a mismatch excision repair system
in the cell, but DNA adducts formed by platinum drugs are poorly
repaired by this system [3,9]. This is due to shielding effect of DNA
binding proteins [9-11]. This error in DNA repair mechanism acti-
vates cell apoptic signals, leading to cell death [12,13].
Fourier Transform Infrared (FTIR) spectroscopy is a well-estab-
lished technology to study interactions of nucleic acids (DNA and
RNA) and proteins with anticancer drugs and other cytotoxic
agents [14-19] in solutions. FTIR has the advantage of generating
structural information of the entire molecule in a single spectrum
as a "snapshot" of all conformations present in the sample. The
technique is ideal for systematic studies of nucleic acids (e.g. se-
quence variations, covalent modifications), since it is fast, non-
destructive, and requires only small amounts of sample. Along
with FTIR, circular dichroism (CD) spectroscopy can be used to
study conformational changes of biomolecules [20,21].
In the present work, carboplatin interaction was investigated
with calf-thymus DNA under physiological conditions. Different
carboplatin/DNA ratios, r = 1/100, 1/50, 1/20, 1/10 and r = 1/40, 1/
20, 1/10, 1/5 were analyzed to study the binding properties of car-
boplatin using FTIR and CD spectroscopic techniques, respectively.
2. Materials and methods
2.1. Materials
Carboplatin and highly polymerized Type I calf-thymus DNA so-
dium salt (sodium content 6%) were procured from Sigma-Aldrich
chemicals (USA) and used without further purification. Purity of
Fig. 1. Chemical structure of (a) cisplatin. (b) carboplatin.
the DNA was checked spectrophotometrically. The absorbance ra-
tio A260/A280 was found 1.86 for the DNA, showing that the sample
was sufficiently free of proteins. Other chemicals and reagents
were of analytical grade and used as supplied. Ultra pure water
was used for preparation of buffer solution and carboplatin solu-
tions of different concentrations.
(a)
were kept 1/40, 1/20, 1/10 and 1/5 with a final DNA concentra-
tion of 2.5 mM.
2.3. FfIR spectra
FfIR spectra were obtained with a Varian 660-IR spectropho-
tometer, equipped with DTGS (deuterated triglycine sulphate)
detector and KBr beam splitter assembly. Spectra were recorded
after 2 h incubation of carboplatin with DNA. Liquid samples were
tightly packed in a liquid cell made up of two ZnSe windows for
infrared measurements. One hundred and twenty-eight scans were
accumulated for each sample in the 4000-650 cm-1 spectral range
with a resolution of 4 cm-1• Background spectra were collected be-
fore each measurement. All the measurements were carried out at
room temperature and controlled ambient humidity of 45% RH. A
spectrum of buffer solution was recorded and subtracted from
the spectra of DNA and carboplatin-DNA complexes [23].
2.2. Preparation of stock solutions
Stock solution of DNA was prepared by dissolving 10 mg of
calf-thymus DNA per milliliter of 10 mM Tris-HCl buffer (pH
7.4). The stock solution was kept at 8 °C for 24 h and stirred occa-
sionally for complete homogenization. Final concentration of the
stock DNA solution was measured spectrophotometrically using
excitation coefficient of 6600 cm-1 [22]. The UV absorbance of
250 times diluted DNA solution was found 0.740 at 260 nm with
a pathlength of 1 cm. The final concentration of DNA stock solu-
tion was 28 mM (molarity of phosphate group). The carboplatin
solution was prepared in ultra pure water and incubated for
96 h for complete hydrolysis. A series of solutions with varying
concentrations of carboplatin were prepared. Carboplatin solu-
tions of different concentration so prepared were added drop by
drop to DNA solutions. The carboplatin/DNA ratios (r) were kept
1/100, 1/50, 1/20 and 1/10. The final concentration of the DNA
was 14 mM in all the solutions used for infrared measurements.
For circular dichroism spectroscopy, the carboplatin/DNA ratios
2.4. CD spectroscopy
CD spectra of pure DNA and its complexes with carboplatin were
recorded with an Applied Photophysics chirascan CD spectropho-
tometer. All spectra were recorded in far UV range (200-320 nm).
Quartz cuvette with a path length of 1 mm was used for sampling.
Three scans were recorded with a scan speed of 1 nm/s and aver-
aged. Sample temperature was kept constant (25°C) during all the
experiment with the help of peltier temperature controller. A spec-
trum of buffer solution was recorded and subtracted from the spec-
tra of DNA and carboplatin-DNA complexes.
3. Results and discussion
3.1. FfIR analysis
Spectral features of carboplatin-DNA complexes are shown in
Fig. 2. Ring vibrations of nitrogenous bases (C=O, C=N stretching),
1/10
-
1/50
c
:::::>
>.
.....
0
.....
- 1/100
..0
.....
«
Free
DNA
1800 1600 1400 1200 1000
Wavenumber (em1)
800 700
3.2. CD analysis
and adenine (N7) of DNA bases. No major shifting is observed for
phosphate asymmetric and symmetric vibrations.
Fig. 3 shows the intensity ratio variations for DNA vibrations as
a function of different carboplatinlDNA molar ratios. Intensity vari-
ations of base vibrations related to G, T, A and C show interesting
pattern after the binding of carboplatin with DNA. At low carbo-
platinlDNA ratio (r = 1/100), intensity of base vibration decreases,
which can be explained by DNA helix stabilization after carbo-
platin interaction. At r = 1/50, the intensity of base vibrations in-
creases due to helix destabilization. The intensity of base and
phosphate vibrations decreases at higher drug concentrations
(r= 1/20 and r= 1/10). This decline in intensity of vibrations is re-
lated to DNA aggregation and condensation at high carboplatin
concentrations [28]. Phosphate stretching (both asymmetric and
symmetric) shows only intensity variations (increase or decrease).
Major shifting in wavenumber was not observed for these vibra-
tions, suggesting minor interaction of carboplatin with phosphate
group of DNA backbone [26,29].
The sugar band at 1053 cm-1 appears as shoulder in the spec-
trum of pure DNA. Intensity of band at 836 cm-1 appears slightly
week and at the same time 937 cm-1 band cannot be seen in pure
DNA spectrum (Fig. 2). This shows a possibility that pure DNA used
in the experiment is slightly denatured.
CD spectra of calf-thymus DNA with varying concentrations of
carboplatin is shown in Fig. 4. There are four major bands in the
spectra for pure DNA, 213 nm (negative), 223 nm (positive),
247 nm (negative) and 277 nm (positive). These are marker CD
bands of double helical DNA in B-conformation [30,31]. When
B-to-A DNA transition occurs, CD band at 213 nm becomes less in-
tense, band at 223 nm shifts toward higher wavelength, and band
at 277 nm becomes more intense [32]. Binding of carboplatin with
DNA does not cause any appreciable shifting in these marker CD
bands, indicative of no alteration in B-DNA conformation (Fig. 4).
This is further confirmed with our infrared spectroscopic results
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Fig. 3. Intensity ratio variations for DNA as a function of different carboplatinfDNA
molar ratios.
POz stretching vibrations (symmetric and asymmetric) and deoxy-
ribose stretching of DNA backbone are confined in the spectral re-
gion 1800-700 cm- 1• Therefore, this particular region is of interest
here. The vibrational bands of DNA at 1710, 1662, 1613 and
1492 cm-1 are assigned to guanine (G), thymine (T), adenine (A)
and cytosine (C) nitrogenous bases, respectively [24-27]. Bands
at 1228 and 1087 cm-1 denote phosphate asymmetric and sym-
metric vibrations, respectively. These are the prominent bands of
pure DNA, which are monitored during carboplatin-DNA interac-
tion at different ratios in this study. Changes in these bands (shift-
ing and intensity) are shown in Fig. 2. After carboplatin addition to
DNA solution, guanine band at 1710 shifts to 1702-3, thymine
band at 1662 shifts to 1655 and adenine band at 1613 shifts to-
wards lower wave number 1609-10 cm-1. These shifting can be
attributed to direct platin binding to guanine (N7), thymine (02)
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of carboplatin-DNA interactions, which shows no changes for
B-DNA marker bands at 1228 cm-1 (P02 ) and 836 cm-1 (phospho-
diester modes). It should be noted that in a B-to-A transition, these
B-DNA marker bands shift from 1228 to 1240 cm-1 (P02 ) and 836
to 810 cm-1 (phosphodiester) [24,25]. We did not observe these
spectral shifting in IR spectra. In the CD spectra, reduction in the
intensity of band at 277 nm is observed for high carboplatin con-
centrations (r= 1/20 and 1/10). This change may be attributed to
DNA aggregation as carboplatin content increases in DNA-drug
complexes [33].
4. Conclusion
The spectroscopic results presented here for carboplatin-DNA
interaction indicate that carboplatin binds with DNA through
guanine N7, thymine 02 and adenine N7, with a little binding pref-
erence towards phosphate backbone of DNA helix. CD and FfIR
spectroscopic analysis revealed that at all concentrations of the
drug used in the experiments, DNA remains in the B family of con-
formations. At higher drug concentrations (r = 1/20 and 1/10) DNA
aggregation was observed.
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